Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

四重療法

  • Home
  • 四重療法
Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice
Posted inCardiology news

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice

Posted by MedXY By MedXY 04/05/2026
A large retrospective study of 52,850 veterans reveals that just 21.2% achieve guideline-directed quadruple therapy for HFrEF, with a median time of 197 days. Socioeconomic barriers, including prescription copays, emerge as critical modifiable factors hindering optimal treatment uptake.
Read More
Residual Clinical Risk and Economic Burden in HFrEF: Insights from the Quadruple Medical Therapy Era
Posted inCardiology Clinical Updates news

Residual Clinical Risk and Economic Burden in HFrEF: Insights from the Quadruple Medical Therapy Era

Posted by MedXY By MedXY 03/14/2026
This review analyzes the real-world one-year outcomes and healthcare costs for HFrEF patients on quadruple therapy, revealing significant residual risk despite optimized pharmacologic management.
Read More
  • 口服司美格鲁肽心血管获益再添证据:SOUL 研究提示高危 2 型糖尿病患者 MACE 风险下降
  • Restoring Cortisol Rhythm May Be Key to Recovery After Cushing Syndrome
  • Long-term Follow-up of Type 1 Diabetes Immunotherapy Trials Finds Reassuring Safety Signals
  • Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up
  • Mitochondrial Rescue in HFpEF: Elamipretide Restores Skeletal Muscle Performance in a Rat Model
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in